

# Hematology Oncology Grand Rounds

## Nagla Karim, MD, PhD

### Updates on management and personalized therapy in Small Cell Lung Cancer

Friday, December 13, 2019

8:00 – 9:15 a.m. SCC 6039



**Nagla Abdel Karim, MD, PhD**  
Professor of Medicine Director of  
Thoracic Oncology and Phase I  
Program Medical Director; Clinical trials  
Program Division of  
Hematology/Oncology

**Professional Practice Gap:** Large gaps exist between general clinical practice and personalized approach in the treatment of small cell lung cancer where a large room exists for improvement. This presentation addresses the gap of learning personalized treatment in small cell lung cancer.

**Objectives:** Upon completion of this session, participants will improve their competence and performance by being able to:

1. Paraphrase the role of chemo-immunotherapy as front line therapy in extensive stage SCLC
2. Paraphrase the maintenance and personalized therapy in SCLC
3. Use future recommendations and clinical trials in SCLC

#### Accreditation Statement

The University of Oklahoma College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The University of Oklahoma College of Medicine designates this live activity for a maximum of 1.25 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

#### Conflict Resolution Statement:

The University of Oklahoma College of Medicine, Office of Office of Continuing Professional Development has reviewed this activity's speaker and planner disclosures and resolved all identified conflicts of interest, if applicable.

**Commercial and In-Kind Support:** This activity received no commercial or in-kind support.

**Policy on Faculty and Presenter Disclosure:** It is the policy of the University of Oklahoma College of Medicine that the faculty and presenters disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s).

**Nondiscrimination Statement:** The University of Oklahoma, in compliance with all applicable federal and state laws and regulations, does not discriminate on the basis of race, color, national origin, sex, sexual orientation, genetic information, gender identity, gender expression, age, religion, disability, political beliefs, or status as a veteran in any of its policies, practices or procedures. This includes, but is not limited to: admissions, employment, financial aid and educational services. Inquiries regarding non-discrimination policies may be directed to: Bobby J. Mason, Institutional Equity Officer, (405) 325-3546, [bjm@ou.edu](mailto:bjm@ou.edu), or visit [www.ou.edu/eoo](http://www.ou.edu/eoo).

**Accommodation Statement:** For accommodations on the basis of disability, call: 271-4022 ext. 48342.

**Disclaimer Statement:** Statements, opinions and results of studies contained in the program are those of the presenters and authors and do not reflect the policy or position of the Board of Regents of the University of Oklahoma ("OU") nor does OU provide any warranty as to their accuracy or reliability.

Every reasonable effort has been made to faithfully reproduce the presentations and material as submitted. However, no responsibility is assumed by OU for any claims, injury and/or damage to persons or property from any cause, including negligence or otherwise, or from any use or operation of any methods, products, instruments or ideas contained in the material herein.



Course #20D12, Hematology Oncology Grand Rounds

Disclosure & Resolution Report

The University of Oklahoma College of Medicine and the Irwin H. Brown Office of Continuing Professional Development must ensure balance, independence, objectivity and scientific rigor in all its activities. We have implemented a process where everyone who is in a position to control the content of an educational activity has disclosed to us all relevant financial relationships with any commercial interest. In addition, should it be determined that a conflict of interest exists as a result of a financial relationship one may have, this will be resolved prior to the activity. This policy is designed to provide the target audience with an opportunity to review any affiliations between the CME organizers and presenters and supporting organizations for the purpose of determining the potential presence of bias or influence over educational content. The following is a summary of this activities disclosure information.

Role	First Name	Last Name	Nature of Relevant Financial Relationship		
			Commercial Interest	What was received?	For what role?
Course Director	Mohamad	Khawandanah, MD	I have no relevant financial relationships or affiliations with commercial interests to disclose.		
Course Contact	Robin	Vinson	I have no relevant financial relationships or affiliations with commercial interests to disclose.		
Moderator/Planning Committee	Adam	Asch, MD	I have no relevant financial relationships or affiliations with commercial interests to disclose.		
Planning Committee	Raid	Aljumaily, MD	I have no relevant financial relationships or affiliations with commercial interests to disclose.		
Planning Committee	J.K.	Feisal, MD	I have no relevant financial relationships or affiliations with commercial interests to disclose.		
Speaker	Nagla	Karim, MD, PhD	Exelixis, Pfizer, BMS	Research Fund	Grant
			Genetech	Speaker Fee	Speaking
			ImmunoCare	Funds	Advisory Board Member

The conflict was resolved by Dr. Karim agreeing that the presentation will not include discussion of any product or services from the listed commercial interests. Dr. Karim will be discussing experimental or off-label drugs and therapies that have not been approved by the FDA